JPWO2020161217A5 - - Google Patents

Claims (5)

A medicament comprising a compound according to any one of claims 1-9. Cardiovascular disease or disorders of fatty acid metabolism or glucose utilization disorders such as hypercholesterolemia; disorders of fatty acid metabolism; diabetes mellitus type 1 and type 2; complications of diabetes such as cataracts, micro- and macrovascular disease, retinopathy , neuropathy, nephropathy, and delayed wound healing, tissue ischemia, diabetic foot, arteriosclerosis, myocardial infarction, acute coronary syndrome, unstable angina, stable angina, stroke, peripheral arterial occlusive disease diseases, cardiomyopathy, heart failure, heart failure, and vascular restenosis; diabetes-related diseases such as insulin resistance (impaired glucose homeostasis), hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol; Claims for the treatment or prevention of obesity, dyslipidemia, hyperlipidemia, e.g., hypertriglyceridemia, metabolic syndrome (Syndrome X), atherosclerosis, and hypertension; and increased levels of high-density lipoprotein 12. The medicine according to Item 11 . Gastrointestinal disease or disorder, e.g., constipation (chronic constipation, functional constipation, chronic idiopathic constipation (CIC), intermittent/sporadic constipation, constipation secondary to diabetes mellitus, constipation secondary to stroke, secondary to chronic kidney disease) Constipation, constipation secondary to multiple sclerosis, constipation secondary to Parkinson's disease, constipation secondary to systemic sclerosis, drug-induced constipation, irritable bowel syndrome with constipation (IBS-C), mixed irritable bowel syndrome ( IBS-M), childhood functional constipation, and opioid-induced constipation); Crohn's disease; primary bile acid malabsorption; irritable bowel syndrome (IBS); inflammatory bowel disease (IBD); 12. A medicament according to claim 11 for the treatment or prevention of reflux disease and its complications such as Barrett's esophagus, bile reflux esophagitis and bile reflux gastritis. Liver diseases or disorders, such as inherited metabolic disorders of the liver; congenital anomalies of bile acid synthesis; congenital anomalies of bile duct running; biliary atresia; stasis; hereditary forms of cholestasis; cerebrotendinous xanthomatosis; secondary defects in BA synthesis; Zellweger syndrome; liver disease associated with cystic fibrosis; syndrome; primary defect in bile acid (BA) synthesis; progressive familial intrahepatic cholestasis (PFIC), e.g., PFIC-1, PFIC-2, PFIC-3, and non-specific PFIC, PFIC after bile diversion , and PFIC after liver transplantation; benign recurrent intrahepatic cholestasis (BRIC), such as BRIC1, BRIC2, and unspecified BRIC, BRIC after bile diversion, and BRIC after liver transplantation; autoimmune hepatitis; liver fibrosis; non-alcoholic fatty liver disease (NAFLD); non-alcoholic steatohepatitis (NASH); portal hypertension; cholestasis; Down's syndrome cholestasis; drug-induced cholestasis; intrahepatic cholestasis of pregnancy (jaundice in pregnancy); intrahepatic cholestasis; extrahepatic cholestasis; parenteral nutrition-associated cholestasis (PNAC); lymphedema cholestasis syndrome 1 (LSC1); primary sclerosing cholangitis (PSC); immunoglobulin G4-associated cholangitis; primary cholangitis; cholelithiasis (gallstones); biliary lithiasis; choledocholithiasis; cholelithic pancreatitis; Calorie's disease; malignant tumor of the bile duct; malignant tumor causing obstruction of the bile tree; pruritus; pancreatitis; chronic autoimmune liver disease leading to progressive cholestasis; liver steatosis; alcoholic hepatitis; acute fatty liver; fatty liver of pregnancy; Dysfunction type 1 (BAS type 1); drug-induced liver injury (DILI); liver fibrosis; congenital liver fibrosis; cirrhosis; Langerhans cell histiocytosis (LCH); idiopathic adult cholangiocytopenia (IAD); idiopathic neonatal hepatitis (INH); non-syndromic intrahepatic cholangiocytopenia (NS PILBD); autosomal recessive intrahepatic cholestasis (North American Indian childhood cirrhosis) (NAIC); hepatic sarcoidosis amyloidosis; necrotizing enterocolitis; serum bile acid-induced toxicities, e.g., cardiac rhythm disturbances in the setting of abnormal serum bile acid profiles (e.g., atrial fibrillation); (cholecardia)”), and skeletal muscle wasting associated with cholestatic liver disease; viral hepatitis (including hepatitis A, hepatitis B, hepatitis C, hepatitis D, and hepatitis E); liver cholangiocarcinoma; gastrointestinal cancer associated with bile acids; and for the treatment or prevention of cholestasis caused by tumors and neoplasms of the liver, biliary tract and pancreas; or cortico in liver disease 12. A medicament according to claim 11 for augmenting steroid therapy. hyperabsorption syndrome (including abetalipoproteinemia, familial hypobetalipoproteinemia (FHBL), chylomicron retention disease (CRD), and sitosterolemia); hypervitaminosis and osteopetrosis; hypertension; 12. A medicament according to claim 11 for glomerular hyperfiltration; and for the treatment or prevention of pruritus of renal failure; or for protection against renal injury associated with hepatic or metabolic disease.